SE0201778D0 - Process for the manufacture of quinoline derivatives - Google Patents

Process for the manufacture of quinoline derivatives

Info

Publication number
SE0201778D0
SE0201778D0 SE0201778A SE0201778A SE0201778D0 SE 0201778 D0 SE0201778 D0 SE 0201778D0 SE 0201778 A SE0201778 A SE 0201778A SE 0201778 A SE0201778 A SE 0201778A SE 0201778 D0 SE0201778 D0 SE 0201778D0
Authority
SE
Sweden
Prior art keywords
manufacture
quinoline derivatives
formula
quinoline
chaineded
Prior art date
Application number
SE0201778A
Other languages
English (en)
Swedish (sv)
Inventor
Karl Jansson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0201778A priority Critical patent/SE0201778D0/xx
Publication of SE0201778D0 publication Critical patent/SE0201778D0/xx
Priority to NZ536768A priority patent/NZ536768A/en
Priority to ES03725956T priority patent/ES2278160T3/es
Priority to DK03725956T priority patent/DK1511732T5/da
Priority to RU2005100054/04A priority patent/RU2291861C2/ru
Priority to AT03725956T priority patent/ATE348814T1/de
Priority to BRPI0311674-3A priority patent/BR0311674A/pt
Priority to SI200330688T priority patent/SI1511732T1/sl
Priority to PL373817A priority patent/PL210259B1/pl
Priority to MEP-2008-656A priority patent/ME00435B/me
Priority to CA2487329A priority patent/CA2487329C/en
Priority to PCT/SE2003/000780 priority patent/WO2003106424A1/en
Priority to CNB038135310A priority patent/CN100418950C/zh
Priority to PT03725956T priority patent/PT1511732E/pt
Priority to KR1020047020088A priority patent/KR100979216B1/ko
Priority to MXPA04012276A priority patent/MXPA04012276A/es
Priority to DE60310554T priority patent/DE60310554T2/de
Priority to JP2004513257A priority patent/JP4584709B2/ja
Priority to YUP-1076/04A priority patent/RS51021B/sr
Priority to EP03725956A priority patent/EP1511732B9/en
Priority to AU2003228195A priority patent/AU2003228195B2/en
Priority to HRP20050028AA priority patent/HRP20050028B1/hr
Priority to UA20041109639A priority patent/UA78310C2/xx
Priority to IL165155A priority patent/IL165155A/en
Priority to ZA200409430A priority patent/ZA200409430B/xx
Priority to IS7550A priority patent/IS2975B/is
Priority to NO20045703A priority patent/NO329162B1/no
Priority to CY20071100295T priority patent/CY1107555T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0201778A 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives SE0201778D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives
UA20041109639A UA78310C2 (en) 2002-06-12 2003-05-14 Method for preparing quinolin derivatives
CNB038135310A CN100418950C (zh) 2002-06-12 2003-05-14 制备喹啉衍生物的方法
KR1020047020088A KR100979216B1 (ko) 2002-06-12 2003-05-14 퀴놀린 유도체의 제조 방법
DK03725956T DK1511732T5 (da) 2002-06-12 2003-05-14 Fremgangsmåde til fremstilling af quinolinderivater
RU2005100054/04A RU2291861C2 (ru) 2002-06-12 2003-05-14 Способ получения производных хинолина
AT03725956T ATE348814T1 (de) 2002-06-12 2003-05-14 Verfahren zur herstellung von chinolinderivaten
BRPI0311674-3A BR0311674A (pt) 2002-06-12 2003-05-14 processo para a preparação de compostos
SI200330688T SI1511732T1 (sl) 2002-06-12 2003-05-14 Postopek za pripravo kinolinskih derivatov
PL373817A PL210259B1 (pl) 2002-06-12 2003-05-14 Sposób wytwarzania pochodnych chinoliny
MEP-2008-656A ME00435B (me) 2002-06-12 2003-05-14 Postupak za dobijanje derivata hinolina
CA2487329A CA2487329C (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives
PCT/SE2003/000780 WO2003106424A1 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives
NZ536768A NZ536768A (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline carboxamide derivatives using an alkane or cycloalkane solvent
PT03725956T PT1511732E (pt) 2002-06-12 2003-05-14 Processo para o fabrico de derivados quinolina
ES03725956T ES2278160T3 (es) 2002-06-12 2003-05-14 Procedimiento para la fabricacion de derivados de quinolina.
MXPA04012276A MXPA04012276A (es) 2002-06-12 2003-05-14 Proceso para la elaboracion de derivados de quinolina.
DE60310554T DE60310554T2 (de) 2002-06-12 2003-05-14 Verfahren zur herstellung von chinolinderivaten
JP2004513257A JP4584709B2 (ja) 2002-06-12 2003-05-14 キノリン誘導体の製造工程
YUP-1076/04A RS51021B (sr) 2002-06-12 2003-05-14 Postupak za dobijanje derivata hinolina
EP03725956A EP1511732B9 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives
AU2003228195A AU2003228195B2 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives
HRP20050028AA HRP20050028B1 (hr) 2002-06-12 2003-05-14 Postupak za proizvodnju derivata kinolina
IL165155A IL165155A (en) 2002-06-12 2004-11-11 A process to create a history of quinoline
ZA200409430A ZA200409430B (en) 2002-06-12 2004-11-23 Process for the manufacture of quinoline derivatives.
IS7550A IS2975B (is) 2002-06-12 2004-11-24 Aðferð til framleiðslu á kvínólín-afleiðum
NO20045703A NO329162B1 (no) 2002-06-12 2004-12-29 Fremgangsmate ved fremstilling av quinolin-derivater
CY20071100295T CY1107555T1 (el) 2002-06-12 2007-03-01 Μεθοδος για την βιομηχανικη παρασκευη παραγωγων κινολινης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives

Publications (1)

Publication Number Publication Date
SE0201778D0 true SE0201778D0 (sv) 2002-06-12

Family

ID=20288148

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives

Country Status (28)

Country Link
EP (1) EP1511732B9 (pl)
JP (1) JP4584709B2 (pl)
KR (1) KR100979216B1 (pl)
CN (1) CN100418950C (pl)
AT (1) ATE348814T1 (pl)
AU (1) AU2003228195B2 (pl)
BR (1) BR0311674A (pl)
CA (1) CA2487329C (pl)
CY (1) CY1107555T1 (pl)
DE (1) DE60310554T2 (pl)
DK (1) DK1511732T5 (pl)
ES (1) ES2278160T3 (pl)
HR (1) HRP20050028B1 (pl)
IL (1) IL165155A (pl)
IS (1) IS2975B (pl)
ME (1) ME00435B (pl)
MX (1) MXPA04012276A (pl)
NO (1) NO329162B1 (pl)
NZ (1) NZ536768A (pl)
PL (1) PL210259B1 (pl)
PT (1) PT1511732E (pl)
RS (1) RS51021B (pl)
RU (1) RU2291861C2 (pl)
SE (1) SE0201778D0 (pl)
SI (1) SI1511732T1 (pl)
UA (1) UA78310C2 (pl)
WO (1) WO2003106424A1 (pl)
ZA (1) ZA200409430B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
NZ567088A (en) 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (ko) 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
CN101578259A (zh) 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
KR20110048571A (ko) 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 2―옥소―1,2―다이하이드로―퀴놀린 조절제
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
PL2458992T3 (pl) 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
DK2542079T3 (da) 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
SG183512A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2590653A4 (en) * 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
SG186430A1 (en) * 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド N−エチル−n−フェニル−1,2−ジヒドロ−4,5−ジ−ヒドロキシ−1−メチル−2−オキソ−3−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
JP6647287B2 (ja) 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
MX379401B (es) 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
AU2021229611A1 (en) 2020-03-03 2022-10-27 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
BR112023000892A2 (pt) 2020-07-23 2023-02-07 Univ Erasmus Med Ct Rotterdam Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor
ES3057099T3 (en) 2021-01-18 2026-02-26 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
AU2022303084A1 (en) 2021-07-02 2024-01-25 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
NZ536768A (en) 2006-10-27
PT1511732E (pt) 2007-03-30
DE60310554T2 (de) 2007-11-29
DK1511732T5 (da) 2007-10-01
HRP20050028B1 (hr) 2013-07-31
PL373817A1 (pl) 2005-09-19
CN100418950C (zh) 2008-09-17
IS2975B (is) 2017-07-15
KR20050016537A (ko) 2005-02-21
AU2003228195B2 (en) 2009-05-28
CA2487329C (en) 2010-11-16
IL165155A0 (en) 2005-12-18
BR0311674A (pt) 2008-01-08
EP1511732A1 (en) 2005-03-09
IS7550A (is) 2004-11-24
PL210259B1 (pl) 2011-12-30
WO2003106424A1 (en) 2003-12-24
CA2487329A1 (en) 2003-12-24
EP1511732B9 (en) 2008-11-12
CY1107555T1 (el) 2013-03-13
JP2005535612A (ja) 2005-11-24
RS51021B (sr) 2010-10-31
RU2005100054A (ru) 2005-07-10
ATE348814T1 (de) 2007-01-15
EP1511732B1 (en) 2006-12-20
HRP20050028A2 (en) 2006-02-28
DE60310554D1 (de) 2007-02-01
RS107604A (sr) 2007-02-05
RU2291861C2 (ru) 2007-01-20
ZA200409430B (en) 2006-02-22
ES2278160T3 (es) 2007-08-01
CN1659146A (zh) 2005-08-24
JP4584709B2 (ja) 2010-11-24
SI1511732T1 (sl) 2007-06-30
MXPA04012276A (es) 2005-04-08
DK1511732T3 (da) 2007-04-30
NO20045703L (no) 2004-12-29
AU2003228195A1 (en) 2003-12-31
ME00435B (me) 2011-10-10
KR100979216B1 (ko) 2010-08-31
IL165155A (en) 2009-11-18
UA78310C2 (en) 2007-03-15
NO329162B1 (no) 2010-08-30

Similar Documents

Publication Publication Date Title
SE0201778D0 (sv) Process for the manufacture of quinoline derivatives
CY1106598T1 (el) Παραγωγα κινολινης και ισοκινολινης, μεθοδος για την παραγωγη αυτων και χρηση αυτων ως αντιφλεγμονωδη μεσα
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
EA200700545A1 (ru) Производные изоксазолина и их применение в качестве гербицидов
DK1613304T3 (da) DPP-IV-inhibitorer
EP1674452A4 (en) NEW 4-PHENYLAMINOBENZALDOXIMDERIVATIE AND ITS USE AS MEK INHIBITOR
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
PE20050077A1 (es) Derivados de 4-pirrolidino-fenil-bencil-eter
NO20044767L (no) Farmasoytisk formulering med modifisert frigjoring
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
NO20032731L (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
NO20055099L (no) Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
MY141020A (en) Novel pparalpha and ppargamma agonists
MEP19508A (en) Process for the preparation of n-amino substituted heterocyclic compounds
WO2003024913A1 (en) SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
NO20031046D0 (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
PE20010029A1 (es) Androgenos oralmente activos
NO20055924L (no) Metode for fremstilling av (2s)-3-(4- {2-[Amino]-2-Oksoetoksy}Fenyl)-2-Etoksypropansyrederivater
NO20054875L (no) Syntese av 2-klormetyl-6-metylbenzosyreestere
TW200621807A (en) Cellulose derivative composition, cellulose derivative film and trialkoxybenzoic acid deriv ative compound
NO20044045L (no) Ny fremgangsmate
TH72657A (th) สารประกอบ